BioAmber (BIOA) Earns Daily Media Impact Score of 0.04

Media coverage about BioAmber (NYSE:BIOA) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BioAmber earned a news sentiment score of 0.04 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.3091967440319 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the media stories that may have impacted Accern’s analysis:

Several brokerages recently issued reports on BIOA. ValuEngine upgraded shares of BioAmber from a “strong sell” rating to a “sell” rating in a research report on Friday, June 23rd. Cowen and Company set a $3.00 target price on shares of BioAmber and gave the stock a “hold” rating in a research report on Monday, July 17th. Finally, Zacks Investment Research lowered shares of BioAmber from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th.

BioAmber (BIOA) traded up 2.1573% during mid-day trading on Thursday, reaching $0.3599. 944,511 shares of the company’s stock traded hands. BioAmber has a one year low of $0.32 and a one year high of $6.50. The firm’s 50-day moving average price is $1.04 and its 200 day moving average price is $2.15. The firm’s market cap is $13.35 million.

BioAmber (NYSE:BIOA) last posted its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by $0.03. BioAmber had a negative return on equity of 56.55% and a negative net margin of 221.82%. The business had revenue of $4.12 million during the quarter, compared to the consensus estimate of $4.09 million. On average, equities analysts forecast that BioAmber will post ($0.58) EPS for the current year.

WARNING: “BioAmber (BIOA) Earns Daily Media Impact Score of 0.04” was originally reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://transcriptdaily.com/2017/09/08/bioamber-bioa-earns-daily-media-impact-score-of-0-04.html.

About BioAmber

BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.

Insider Buying and Selling by Quarter for BioAmber (NYSE:BIOA)

Receive News & Ratings for BioAmber Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAmber Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply